

Ref No. NLL/CS/2022-206

November 21, 2022

National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051

Symbol: NECLIFE

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001

Scrip Code: 532649

Sub: Disclosure of Related Party Transactions.

Ref.: SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021

Dear Sir/ Madam,

Pursuant to Compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and captioned circular, please find enclosed the disclosure on Related Party Transactions for half year period from April 01, 2022 to September 30, 2022.

This is for your information and records.

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjiv Goyal)
Chairman & Managing Director

Encl. As above

FOR HALF YEAR ENDED ON SEPTEMBER 30, 2022										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/ subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
S. No.	Details of the party (listed entity/ subsidiary) entering into the transaction		Details of the Counterparty			Type of related party transactions	Value of the related party transaction as approved by the audit committee	Remarks on approval by Audit Committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary					Opening Balance	Closing Balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ Unsecured	Purpose for which the funds will be utilized by the ultimate recipient of funds (end-usage)
1	Nectar Lifesciences Limited		Mr. Sanjiv Goyal		Chairman & Managing Director	Managerial Remuneration	Note 1	Note 1	102.60	15.04	3.15	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
2	Nectar Lifesciences Limited		Mr. Dinesh Dua		Executive Director	Managerial Remuneration	Note 1	Note 1	22.98	3.87	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
3	Nectar Lifesciences Limited		Mr. Puneet Sud		Wholetime Director	Managerial Remuneration	Note 1	Note 1	1.10	-	0.68	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
4	Nectar Lifesciences Limited		Mr. Amit Chadah		Chief Executive Officer	Salary to KMP	Note 1	Note 1	38.04	3.11	3.19	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
5	Nectar Lifesciences Limited		Mr. Sandeep Goel		Chief Financial Officer	Salary to KMP	Note 1	Note 1	13.40	1.33	1.68	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
6	Nectar Lifesciences Limited		Ms. Anubha		Company Secretary	Salary to KMP	Note 1	Note 1	2.36	0.35	0.35	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
7	Nectar Lifesciences Limited		Mr. Ajay Swaroop		Independent Director	Sitting Fees	Note 1	Note 1	1.00	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
8	Nectar Lifesciences Limited		Dr. Rupinder Tewari		Independent Director	Sitting Fees	Note 1	Note 1	0.95	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
9	Nectar Lifesciences Limited		Dr. Kuldip Kumar Bhasin		Independent Director	Sitting Fees	Note 1	Note 1	0.95	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
10	Nectar Lifesciences Limited		Ms. Meena Verma		Nominee Director	Sitting Fees	Note 1	Note 1	0.40	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
11	Nectar Lifesciences Limited		Mrs. Indu Pal Kaur		Independent Director	Sitting Fees	Note 1	Note 1	0.45	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
12	Nectar Lifesciences Limited		Nectar Lifesciences Charitable Foundation		Promoter/Director and KMPs have significant Influence	CSR expenditure	Note 1	Note 1	9.09	-	-	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
13	Nectar Lifesciences Limited		Nectar Lifesciences USA LLC		Wholly owned subsidiary	Purchase/ Sale/ Trade receivables/ Payable etc.	Not Applicable	Not Applicable	-	94.24	94.24	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
14	Nectar Lifesciences Limited		Mr. Amit Chadah		Chief Executive Officer	Unsecured Interest free loan given	Not Applicable	Not Applicable	-	30.62	30.62	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	
15	Nectar Lifesciences Limited		Sanjiv (HUF)		Promoter/Director have significant Influence	Unsecured Interest free loan received	Not Applicable	Not Applicable	-	1,000.00	1,000.00	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	N.A.	

Note 1. Audit Committee approval has been received on all perpetual transactions for the term of Managerial Remuneration/ Salary to KMPs/ Sitting Fee/ CSR Expenditure. Further approvals from Board / members have been received as per the provisions of the Companies Act, 2013

Note 2. Opening and closing balance of Investment in subsidiaries during the half year ended September 30, 2022 are not given where there was no transaction .

For Nectar Lifesciences Limited

Date: 21-11-2022
Place: Chandigarh

(Sushil Kapoor)
Chief Financial Officer